📣 VC round data is live. Check it out!
- Public Comps
- GeneDx
GeneDx Valuation Multiples
Discover GeneDx's revenue and EBITDA valuation multiples and M&A history, alongside public comparables like Dian Diagnostics Group, Indegene, Clover Health, Eckert & Ziegler and more.
GeneDx Overview
About GeneDx
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.
Founded
2000
HQ

Employees
1.3K
Website
Financials (LTM)
EV
$2B
Valuation Multiples
Start free trialGeneDx Financials
GeneDx reported last 12-month revenue of $449M and EBITDA of $25M.
In the same LTM period, GeneDx generated $314M in gross profit, $25M in EBITDA, and $24M in net income.
Revenue (LTM)
GeneDx P&L
In the most recent fiscal year, GeneDx reported revenue of $428M and EBITDA of $40M.
GeneDx is profitable as of last fiscal year, with gross margin of 70%, EBITDA margin of 9%, and net margin of 10%.
Financial data powered by Morningstar, Inc.
GeneDx Stock Performance
GeneDx has current market cap of $2B, and enterprise value of $2B.
Market Cap Evolution
GeneDx's stock price is $53.10.
GeneDx share price increased by 2.1% in the last 30 days, and decreased by 42.1% in the last year.
GeneDx has an EPS (earnings per share) of $1.41.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | 2.1% | 2.1% | -17.3% | -42.1% | $1.41 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialGeneDx Valuation Multiples
GeneDx trades at 3.5x EV/Revenue multiple, and 62.7x EV/EBITDA.
EV / Revenue (LTM)
GeneDx Financial Valuation Multiples
As of June 3, 2026, GeneDx has market cap of $2B and EV of $2B.
GeneDx has a P/E ratio of 66.8x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified GeneDx Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


GeneDx Margins & Growth Rates
GeneDx grew revenue by 12% but EBITDA decreased by 90% in the last fiscal year.
In the most recent fiscal year, GeneDx reported gross margin of 70%, EBITDA margin of 9%, and net margin of 10%.
GeneDx Margins
GeneDx Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
GeneDx Operational KPIs
GeneDx's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.2M for the same period.
GeneDx's Rule of 40 is 13% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
GeneDx's Rule of X is 31% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
GeneDx Competitors
GeneDx competitors include Dian Diagnostics Group, Indegene, Clover Health, Eckert & Ziegler, JMDC, Personalis, Genus, CareDx, Vazyme Biotech and Azenta.
Most GeneDx public comparables operate across Diagnostics & Genomics, Health Data & Analytics, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 1.1x | 1.1x | 12.8x | 11.2x | |||
| 3.1x | 3.0x | 16.6x | 17.0x | |||
| 0.8x | 0.7x | 75.4x | 44.3x | |||
| 3.0x | 3.0x | 9.9x | 10.1x | |||
| 5.0x | 4.0x | 18.1x | 15.2x | |||
| 13.9x | 13.2x | (13.7x) | (10.8x) | |||
| 2.5x | 2.5x | 14.1x | 12.7x | |||
| 2.6x | 2.4x | 30.9x | 24.4x | |||
This data is available for Pro users. Sign up to see all GeneDx competitors and their valuation data. Start Free Trial | ||||||
GeneDx VC Funding History
Before going public, GeneDx raised $241M in total equity funding, across 2 rounds.
Last private valuation of GeneDx was $1B, after raising $121M in July 2020 from BlackRock, Blackstone, Connecticut Innovations, and 5 other investors.
GeneDx Funding Rounds
Acquisitions by GeneDx
GeneDx has acquired 2 companies to date.
Last acquisition by GeneDx was on April 16th 2025. GeneDx acquired Fabric Genomics for $51M (EV/Revenue multiple available to Pro users).
Latest Acquisitions by GeneDx
| Description | Fabric Genomics is a genomic analysis platform delivering clinical decision support for precision medicine in hereditary diseases and oncology. Its end-to-end software processes whole-genome sequencing data with AI algorithms to identify variants and recommend therapies. Oakland-headquartered, Fabric Genomics collaborates with labs like Boston Children's Hospital and national programs in the Middle East. Founded in 2014, the platform analyzes over 100,000 genomes annually, reducing diagnostic turnaround to under 10 days. | GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services. |
| HQ Country | ||
| HQ City | San Francisco, CA | Washington, DC |
| Deal Date | 16 Apr 2025 | 18 Jan 2022 |
| Valuation | $51M | $623M |
| EV/Revenue | ||
| EV/EBITDA | ||
This data is available for Pro users. Sign up to see all GeneDx acquisitions and their M&A valuation multiples. Start Free Trial | ||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout GeneDx
| When was GeneDx founded? | GeneDx was founded in 2000. |
| Where is GeneDx headquartered? | GeneDx is headquartered in United States. |
| How many employees does GeneDx have? | As of today, GeneDx has over 1K employees. |
| Who is the CEO of GeneDx? | GeneDx's CEO is Katherine A. Stueland. |
| Is GeneDx publicly listed? | Yes, GeneDx is a public company listed on Nasdaq. |
| What is the stock symbol of GeneDx? | GeneDx trades under WGS ticker. |
| When did GeneDx go public? | GeneDx went public in 2021. |
| Who are competitors of GeneDx? | GeneDx main competitors include Dian Diagnostics Group, Indegene, Clover Health, Eckert & Ziegler, JMDC, Personalis, Genus, CareDx, Vazyme Biotech, Azenta. |
| What is the current market cap of GeneDx? | GeneDx's current market cap is $2B. |
| What is the current revenue of GeneDx? | GeneDx's last 12 months revenue is $449M. |
| What is the current revenue growth of GeneDx? | GeneDx revenue growth (NTM/LTM) is 17%. |
| What is the current EV/Revenue multiple of GeneDx? | Current revenue multiple of GeneDx is 3.5x. |
| What is the current EBITDA of GeneDx? | GeneDx's last 12 months EBITDA is $25M. |
| What is GeneDx's EBITDA margin? | GeneDx's last 12 months EBITDA margin is 6%. |
| What is the current EV/EBITDA multiple of GeneDx? | Current EBITDA multiple of GeneDx is 62.7x. |
| How many companies GeneDx has acquired to date? | As of June 2026, GeneDx has acquired 2 companies. |
| What was the largest acquisition by GeneDx? | $623M acquisition of GeneDx on 18th January 2022 was the largest M&A GeneDx has done to date. |
| What companies GeneDx acquired? | GeneDx acquired GeneDx and Fabric Genomics. |
| In how many companies GeneDx has invested to date? | GeneDx hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to GeneDx
Lists including GeneDx
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.
